A PHASE II TRIAL OF COMBINED MODALITY THERAPY PLUS CETUXIMAB IN HIV-ASSOCIATED A

联合疗法加西妥昔单抗治疗 HIV 相关 A 患者的 II 期试验

• 批准号: 8167098
• 负责人: RONALD T. MITSUYASU
• 金额: $ 1.05万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167098
• 关键词: Acquired Immunodeficiency Syndrome; Anus; CD4 Lymphocyte Count; Cetuximab; Combined Modality Therapy; Computer Retrieval of Information on Scientific Projects Database; Cytology; Development; Failure; Funding; Grant; HIV; Human Papillomavirus; Incidence; Infection; Institution; Malignant neoplasm of anus; Phase; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Viral Load result

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: Primary Aim: To detect whether the addition of cetuximab to standard chemoradiation reduces the local failure rate by at least 50% Secondary Aims: 1) To characterize the effect of CMT plus cetuximab on the underlying HIV condition by describing changes in viral load, CD4 counts, incidence of opportunistic illnesses including the development of AIDS during and in the first year after CMT. 2) To evaluate the effect of CMT of anal cancer on anogenital HPV infection and anal cytology.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 具体目标： 主要目的：检测在标准化放疗基础上加用西妥昔单抗是否可将局部失败率降低至少50% 次要目标： 第一章 通过描述CMT期间和CMT后第一年内病毒载量、CD 4计数、机会性疾病（包括AIDS）发生率的变化，描述CMT联合西妥昔单抗对基础HIV疾病的影响。 （二） 目的探讨肛管癌CMT对肛门生殖器HPV感染及细胞学的影响。